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Abstract  
BACKGROUND: Myotonic dystrophy type 1 (DM1) is the most prevalent degenerative neuromuscular 
disease in adults. Knee extensor (KE) maximal strength loss is a strong indicator of physical limitations in 
DM1. A reliable, precise and accessible maximal strength evaluation method needs to be validated for this 
slowly progressive disease.   
OBJECTIVE: This paper aims to assess the intra-rater reliability, the standard error of measurement (SEM), 
the minimal detectable change (MDC), and the concurrent validity of quantified muscle testing (QMT) 
using a handheld dynamometer with a gold standard: the Biodex isokinetic device.  
METHODS: Nineteen men with the adult form of DM1 participated in this study by attending 2 visits 
spaced by one week. The evaluation of KE muscle strength with QMT was completed on the first visit and 
the same QMT evaluation in addition to the maximal muscle strength evaluation using an isokinetic device 
were performed on the second visit.  
RESULTS: The intra-rater reliability was excellent with an intraclass correlation coefficient (ICC) of 0.98 
(0.96-0.99: 95% confidence interval). SEM and MDC values were 1.05 Nm and 2.92 Nm, respectively. 
Concurrent validity of QMT of KE muscle group with the Biodex was also excellent with a Spearman’s 
correlation of ρ = 0.98.  
CONCLUSIONS: The excellent concurrent validity and intra-rater reliability, and the small SEM and MDC 
of the QMT make this test a method of choice, in either a clinical or research setting, to precisely evaluate 
muscle strength impairments of the KE in men with DM1.  
Keywords: myotonic dystrophy type 1, muscle strength, quantified muscle testing, isokinetic device, intra-
rater reliability, concurrent validity 
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1 Introduction  
Myotonic dystrophy type 1 (DM1) is the most prevalent degenerative hereditary myopathy in adults and is 
caused by an abnormal CTG triplet repetition on the myotonic dystrophy protein kinase (DMPK) gene [1]. 
The age of onset of the disease along with its severity are mildly correlated with the number of CTG 
repetitions [2]. In general, the severity of the symptoms is also correlated with the age of onset of the 
disease. The disease is classified into five different phenotypes according to the age of onset: congenital, 
infantile, juvenile, adult or classic and late [3]. DM1 is a multisystemic disease, which affects 
cardiovascular, endocrine, neurological and musculoskeletal systems, to name a few [4]. Neurological 
affections can include cognitive impairments, daytime sleepiness and apathy [4-6]. Skeletal muscles are 
notably affected and patients with the disease experience slowly progressive muscle atrophy and weakness 
[4, 7]. In the adult form, it has been demonstrated that affected people lose 24.5 to 52.8% of their maximal 
strength on a 9-year period depending on the muscle group evaluated [8]. Furthermore, it has been reported 
that the disease affects skeletal muscles differently in men and women[8-10]. Petitclerc et al. have 
demonstrated that muscle weakness in knee extension and ankle dorsiflexion is a very good indicator of 
physical limitations in people with the adult or late phenotype of DM1 [11]. They also showed that knee 
extensors (KE) muscle strength was the main explanatory factor of performance variations in the timed up 
and go test [11]. Lower extremity weakness is also one of the main predictors of disruption in participation 
of the affected individuals [12, 13]. It is therefore important that lower extremity maximal strength, namely 
for the KE and the ankle dorsiflexors, can be robustly and finely measured in this population. These precise 
measurements will not only be useful to follow the disease’s progression, but also to verify the efficiency 
of treatments in the context of clinical follow-ups or clinical trials timeframes. Intra-rater reliability and the 
standard error of measurement (SEM) for the ankle dorsiflexors maximal strength using a handheld 
dynamometer have already been calculated for this population [14]. However, such data do not yet exist 
for the KE muscle group, another important clinical indicator of physical limitations in DM1 adult and late 
phenotypes.  
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One method that is commonly used in DM1 to measure muscle strength is manual muscle testing (MMT) 
as it is incorporated in the muscle impairment rating scale (MIRS), a tool designed to rate the severity of 
muscle impairments in DM1 [15]. However, MMT has been demonstrated to be unreliable in DM1 as well 
as in other populations [14, 16, 17]. Indeed, it has been shown that for the same muscle strength expressed 
in Nm, DM1 participants could be classified in multiple MMT scores [16]. More importantly, DM1 
participants that were considered to have no muscle impairments according to the MMT, showed 
significantly lower maximal strength than their predicted values [16]. In addition, it has been shown that to 
detect KE strength loss with MMT, a person with DM1 must have lost on average 45.2% of its maximal 
strength [18]. A more discriminant and precise method to evaluate maximal muscle strength therefore needs 
to be validated in this population, not only for research purposes but for clinical practice as well. Isokinetic 
devices such as the Biodex system 4 (Biodex Medical Systems, Shirley, NY, USA) are considered to be the 
gold standard for maximal muscle strength evaluation. However, these devices have many inconveniences, 
namely in a clinical setting: they are very expensive, cannot be moved easily, are quite time consuming to 
use, and some testing positions are difficult to adopt by DM1 patients [19]. A compromise between the 
affordability of MMT and the high precision and good reliability and validity of the isokinetic devices 
resides with quantitative muscle testing (QMT) techniques using a handheld dynamometer [19]. Handheld 
dynamometry is widely used in physiotherapy practice, however, there is a lack of standardisation in the 
methods across studies [20]. In order to carry out an adequate handheld dynamometry protocol, some 
elements must be respected to diminish biases. First of all, make tests have been shown to be more reliable 
[21] and less likely to cause injury than break tests [22]. Next, positions that eliminate gravity for the 
movement of interest avoid having to consider the weight of the limb in the calculation of muscle torques 
[23]. Thereafter, the main agonist muscles should be placed at mid-length to allow the generation of 
maximal strength during contraction [24]. Lastly, whenever possible, the involvement of the evaluator in 
providing the physical resistance should be minimized. The handheld dynamometry QMT technique 
presented in this study met all those criteria [23]. 
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The main objective of this paper was to evaluate the reliability and validity of the evaluation of the maximal 
isometric muscle strength (MIMS) of the KE using the QMT technique in men with the adult form of DM1. 
More specifically, this study aims to: 1) evaluate the intra-rater reliability along with the SEM and the 
minimal detectable change (MDC) of the QMT technique and 2) to evaluate the concurrent validity of the 
QMT technique with a Biodex isokinetic device.  
2 Materials and methods 
Men with the adult form of DM1 aged between 30 and 65 years old were recruited from the neuromuscular 
clinic of Jonquière, Québec, Canada. DM1 diagnosis had to be confirmed by genetic analysis. To limit 
heterogeneity in the group, recruitment was restrained to men. Participants had to be able to walk without 
aids, give their informed consent, reside in the Saguenay—Lac-Saint-Jean region and have no 
contraindications to maximal resistance testing. The study was approved by the Ethics Review Board of the 
Centre intégré universitaire de santé et de services sociaux (CIUSSS) of Saguenay—Lac-Saint-Jean 
(Québec, Canada) and all participants gave their written informed consent. 
The evaluations were done on two separate visits. In the first visit, participants completed QMT for the KE 
on both legs. One week later, the participants did both: 1) QMT for the KE on both legs again and 2) 
isometric muscle testing of the right KE on the Biodex isokinetic device with a mandatory 30 minutes 
sitting rest between the two different testing methods. The participants were randomly assigned to either 
complete the QMT first or the Biodex. The weight of all participants was measured using the InBody 570 
scale (InBody, Ottawa, Canada). All tests were administered by the same, previously trained, physical 
therapist (M-P R).                
2.1 Quantified muscle testing 
The QMT protocol used in this study to evaluate the MIMS was developed by Hébert et al. to ensure the 
best reproducibility of handheld dynamometry evaluations [23]. The handheld dynamometer used was the 
MEDupTM linear electronic handheld dynamometer (Atlas medic, Québec, Canada). Participants were 
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seated with their hip and knee flexed at a 90-degree angle (Figure 1-A). A pen mark was made on the 
patient’s leg 10 cm above the inferior edge of the lateral malleolus as a position indicator for the proximal 
edge of the dynamometer. The dynamometer was positioned perpendicular with the leg and secured in place 
with a certified strap. Participants were asked to push gradually against the dynamometer until they reached 
their maximal strength and to hold the contraction until they were told to release. During the test, patients 
were given a vigorous standardized encouragement that lasted 10 seconds to ensure that peak force was 
reached. The encouragements started with a neutral tone and gradually progressed in intensity, the evaluator 
began with “go ahead, push” and continued with the use of the words “push”, and “stronger” alternatively 
and the participant’s name to end with “and now release” once the 10 seconds were completed. Participants 
were allowed to stabilize themselves by holding the edge of the table with both hands, with their elbows in 
full extension to avoid them to bend forward or backward during the tests. At least two trials were done: if 
the trials had more than 10% difference, a third or fourth trial was done as needed. The mean of the two 
closest trials for each leg was kept for analysis. This procedure was chosen to ensure the result was as close 
as possible to the real maximal strength and minimize possible errors during the test (compensations, sub-
maximal contractions, etc.). Participants were given a 30 second rest between trials. The lever arm length 
was calculated as being the perpendicular distance between the knee joint line and the pen mark to which 
half the width of the dynamometer’s cushion was added. The knee joint line was chosen as the reference 
point to the knee to allow better intra and inter-rater reproducibility [23]. 
2.2 Isokinetic device 
The isokinetic device used was the Biodex isokinetic dynamometer (Biodex Medical Systems, Shirley 
(NY), USA). Participants were seated according to the manufacturer’s instructions with all belts fastened 
and hip and knee at 90-degree angles (Figure 1-B). The center of the isokinetic device was positioned to be 
aligned with the right knee’s joint center of rotation: at the inferior part of the lateral condyle. To evaluate 
the MIMS, the isokinetic device was programmed to record three isometric 10-second trials with 30 seconds 
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of rest between trials. The participants were given the same vigorous standardized encouragements during 
the isokinetic device testing as during the QMT.  
2.3 Data analysis  
QMT intra-rater reliability was calculated by comparing the average measure of the two closest trials of 
both legs (4 measurements) from week 1 to the average measure from week 2. Intraclass correlations 
coefficients (ICC) with a 95% confidence interval and coefficient of determination (R2) were used to assess 
reliability. Bland and Altman plots were also used for further analysis purposes and confirm adequate 
reproducibility between week 1 and week 2. In each plot, the mean of the difference along with the 95% 
confidence interval bounds are presented. A standard error of the measurement (SEM) was also calculated 
from this data. The minimal detectable change (MDC) with a 95% confidence interval was calculated using 
the formula MDC = 1.96 x SEM × √ 2, where 1.96 is derived from the 95% confidence interval. This value 
was also converted in percentage compared to the average of the group, where MDC% = (MDC/average) 
* 100.   
Concurrent validity between the QMT and the Biodex isokinetic device was calculated using the average 
of the closest two trials of the isokinetic device testing (right leg only) compared to the closest two trials of 
the right leg with QMT technique, both obtained on week two. Spearman’s correlation and R2 were used to 
assess correlation between the two evaluation methods. Bland and Altman plots were also used to evaluate 
the agreement between the two different measurements techniques used. 
3 Results 
3.1 Participants 
A convenience sample of 21 male participants with DM1 was recruited. One participant dropped out before 
his first visit and another was excluded because he was not able to understand the instructions related to 
maximal muscle strength evaluations (QMT and isokinetic device). If possible, the participants were 
evaluated on the same time of day for both evaluations to avoid different levels of fatigue: 14/19 were 
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evaluated at the same time of day and 5/19 were evaluated at different times due to work schedule 
constrains. Out of those 5 patients, none were evaluated with a morning/evening extreme. Participant’s 
characteristics are found in Table 1. Patients are presented according to their KE maximal strength obtained 
during Biodex testing. 
3.2 Intra-rater reliability of the QMT 
An excellent ICC (ICC > 0.90) [25] of 0.98 with a 95% confidence interval ranging from 0.96 to 0.99 was 
obtained by comparing the QMT results of week 1 and week 2 (Table 2). The SEM obtained was fairly low 
(1.05 Nm) along with a low MDC (2.92 Nm) and MDC% (2.69%). As seen on the Bland and Altman plot 
of the Figure 2, the mean of the difference between week 1 and 2 is very small (3.37 Nm), meaning that 
repeating this method would lead to similar results over time. A paired t-test done between week 1 and 2 
(Table 1, intra-rater reliability rows) confirms this with p = 0.16.  
3.3 Concurrent validity between the QMT and the isokinetic device 
A very high correlation was found between the QMT and Biodex isokinetic device for the evaluation of 
MIMS in men with DM1 (R2 = 0.94 and ρ = 0.98) (Table 3). However, the mean difference between the 
methods in accordance to the Bland and Altman plot (Figure 3) is 23.67 Nm (p < 0.001), which means that 
the QMT technique on average provides lower values of MIMS than the isokinetic device.  
4 Discussion 
The aim of this study was to determine the intra-rater reliability, the SEM, the MDC and the concurrent 
validity with the isokinetic device of the QMT technique in men with the adult form of DM1. The intra-
rater reliability was found to be excellent (ICC > 0.90) [25] with an ICC of 0.98. The 95% confidence 
interval was also very high, ranging from 0.96 to 0.99 and thus remains excellent throughout its range. The 
SEM and MDC were also very low at 1.05 Nm and 2.92 Nm, respectively. This means that a change of 
1.05 Nm can be considered into the error of the measurement but any change greater than 2.92 Nm can be 
considered as the result of the patient’s maximal strength variation. The SEM obtained for the MIMS of 
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KE is comparable to the one previously published for ankle dorsiflexion in DM1, which is 1.0 Nm [14]. 
Considering that the strength of the KE is much higher than the ankle dorsiflexors, this later finding 
confirms that, when using an appropriate QMT method, the capacity to resist of the evaluator does not 
impact at all on the measurement error. The same QMT protocol was used in healthy children aged from 
13 to 17.5 years old: while the SEM is comparable for ankle dorsiflexion (0.5 Nm for girls and 1.0 Nm for 
boys), the SEM for knee extension was higher (3.8 Nm for girls and 4.5 for boys) than the one we obtained 
[23]. This means that despite the possible difficulties in assessing maximal strength in DM1 related to 
cognitive impairment and/or apathy, QMT for KE and ankle dorsiflexors remain highly reliable and 
sensitive to change in this population. These results are quite encouraging and useful for clinicians that 
have to finely monitor their patient’s strength and evaluate the efficacy of their interventions in this slowly 
progressive disease. Specifically, our results showed that a variation of 2.92 Nm (5.9-6.1% of the maximal 
KE strength) in KE muscle strength evaluated with QMT technique is clinically significant, in comparison 
with MMT technique where 45.2% of maximal strength loss is required to be able to conclude about the 
presence of KE muscle impairments [18].  
A strength of the present results is that many sources of biases have been controlled for. The physiotherapist 
in charge of administrating all the tests was trained with the QMT and isokinetic device evaluation 
techniques. Parameters previously mentioned, such as agonist muscle length and gravity were controlled 
for. Another important factor that was controlled was the encouragements provided to the participants. 
While it is important that the participants are adequately stimulated throughout all populations, it is 
particularly important in DM1 since apathy is very frequent in this disease [6]. All of these factors, as well 
as a highly standardized technique should be respected while evaluating maximal muscle strength. And 
finally, the use of a high-quality handheld dynamometer both in terms of load cell precision and excellent 
equipment ergonomics has also contributed to obtain precise and reproducible measure.  
Regarding concurrent validity, the Spearman’s correlation and R2 between the QMT technique and the 
isokinetic device are also very high (R2 = 0.94 and ρ = 0.98), meaning that the QMT compares to a well-
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established test considered as the gold standard, the Biodex. In other words, the higher the individual scores 
on the QMT, the higher their score on the Biodex and likewise, the lower the score on QMT, the lower the 
score on the Biodex. However, according to the Bland an Altman plot, we have found that there was on 
average a difference of 23.7 Nm between the QMT and Biodex method. The plot also shows that the 
stronger the patient, the more likely there is to be higher values obtained with the Biodex. There are different 
methodological factors to consider explaining this systematic difference that are discussed in the next 
section.  
4.1 Study limitations 
One important difference between the QMT and the Biodex comes from the measurement of the lever arm. 
In the QMT, in order to assure a better reproducibility, the knee joint line was chosen as the anatomical 
reference point for the axis of knee joint rotation [23], while with the isokinetic device, it was the inferior 
part of the lateral femoral condyle. While these two anatomical structures are very close, the lateral condyle 
of the knee is slightly above the knee joint line, giving a longer lever arm during the isokinetic device 
testing, thus leading to the calculation of higher moments of KE muscle strength. The second difference 
between the two evaluation methods would be the trunk stabilization. For the isokinetic device, the 
participants are tightly strapped to the chair, giving them the most possible stable position (Figure 1-B). In 
the QMT, participants are simply seated on an evaluation table (Figure 1-A) and they had to stabilize 
themselves. This double task could lead to submaximal contractions of the KE in this population known to 
have cognitive impairments. In line with this, it has already been shown that double tasks negatively 
influence gait patterns in DM1 [26]. Also, during the QMT evaluation, we cannot exclude that the 
stabilization of patients by holding the front of the examination table may have resulted in a slight hip 
flexion, leading to a reduced length of the rectus femoris of the quadriceps. Being one of the main agonists 
of knee extension, a change in length of the rectus femoris in favor of a reduction of muscle length may 
explain some of the strength loss as the maximal strength of each muscle depends on its contraction length 
where in general mid-length will provide the greater muscle strength production [24].  
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5 Conclusion 
Precisely measuring KE muscle strength in DM1 is fundamental as this muscle group is essential to 
maintain adequate mobility and reduce as much as possible physical limitations in this population. Also, in 
this slowly progressive disease, it is even more important to use a measure that is sensitive with a very small 
error in order to detect any short-term changes of muscle strength. Next, as it is easy and important to train 
the KE, the QMT method would allow clinicians to rapidly verify if the provided training is successful or 
not. The current findings are encouraging, as QMT has shown excellent intra-rater reliability, a very small 
error of measurement, and a good concurrent validity with the Biodex meaning that clinicians could use 
this method to finely monitor the muscle function of their DM1 patients with confidence. Moreover, the 
QMT technique proposed is user friendly, versatile, affordable and portable, and would therefore be an 
excellent method to evaluate maximal muscle KE strength in subjects with DM1. 
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Tables 
Table 1: 
Participant’s characteristics and maximal muscle strength of their KE. 
  
 
 
 
 
Values used for the intra-rater 
reliability 
Values used for the concurrent 
validity 
Patient 
number Age  
Age of 
diagnosis Weight  Height CTG  
QMT * 
week 1 
QMT * 
week 2 
QMT right 
leg‡ 
 week 2 
Isokinetic 
device right 
leg‡ 
week 2 
 Years Years kg cm n Nm Nm Nm Nm 
1 40 16 42.9 178 600 9.40 8.82 5.84 7.15 
2 51 27 71.1 173 1300 24.83 27.98 23.21 23.35 
3 37 32 56.7 170 500 40.45 40.87 37.16 36.55 
4 56 22 65.3 176 1000 76.08 77.95 70.24 73.15 
5 35 18 65.8 169 800 90.21 83.06 79.55 99.85 
6 54 20 66.5 163 1200 97.57 82.62 78.55 103.20 
7 48 35 71.2 172 250 107.44 95.70 89.13 113.25 
8 57 52 68.8 170 400 89.45 98.13 91.92 117.00 
9 36 29 51.0 169 400 90.76 87.79 89.61 118.70 
10 37 34 61.4 174 350 127.75 122.13 123.84 127.45 
11 60 39 70.7 167 400 98.23 114.99 119.87 144.20 
12 41 6 95.4 170 400 156.40 116.85 106.78 160.40 
13 61 55 99.0 170 80 132.80 131.87 136.40 170.65 
14 35 32 70.1 177 80 156.32 152.76 144.63 173.55 
15 41 28 109.9 172 400 135.58 126.82 134.07 185.75 
16 61 53 76.6 162 65 141.81 145.92 148.87 192.15 
17 51 44 92.7 168 70 179.17 190.23 197.18 198.70 
18 40 26 100.6 176 150 162.61 160.96 161.87 203.80 
19 32 25 114.8 182 250 175.59 162.96 165.29 204.95 
Mean 
(SD) 
46 
 (10) 
32 
(13) 
76 
 (20)  
172 
(6) 
458 
(372) 
110.13 
(49.16) 
106.76 
 (47.62) 
105.47 
 (50.33) 
129.15 
 (61.50) 
 
Table legend: *Average of the two closest values of right and left leg (4 measurements). ‡ Average of the 
two closest values of right leg (2 measurements).  
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Table 2: 
Intra-rater reliability, SEM and MDC of the evaluation of maximal muscle strength of the KE muscle 
groups at two time points separated by one week 
 
QMT of KE 
(week 1 vs week 2) 
R2 ICC 95% confidence 
interval 
SEM MDC MDC% 
0.94 0.98 0.96-0.99 1.05 Nm 2.92 Nm 2.69% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
 
 
 
Table 3: 
Concurrent validity of QMT technique with an isokinetic device for the evaluation of maximal muscle 
strength of KE 
 
Concurrent validity between 
the QMT and the isokinetic 
device for the KE 
R2 Spearman’s (ρ) 
0.94 0.98 
(p < 0.001) 
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Figure legends 
Figure 1 A and B: Illustrations depicting the two different evaluation methods. A: The QMT technique 
using a handheld dynamometer. B: The isokinetic device technique. All line art was simplified from 
photographs to facilitate comprehension of the setup.  
 
Figure 2: Bland Altman plot of the difference in KE maximal strength between week 1 and 2 using QTM 
for each participant (p = 0.16). The upper and lower limits represent the 95% confidence interval. Results 
are presented in Nm.  
 
Figure 3: Bland Altman plot of the difference between the handheld dynamometry and the isokinetic device 
for each participant (p < 0.001). The upper and lower limits represent the 95% confidence interval. Results 
are presented in Nm. 
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Figures 
Figure 1 A and B 
 
 
Figure 2 
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Figure 3  
 
